Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer.
about
Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological featuresNovel immunotherapeutic strategies of gastric cancer treatmentThe relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell CarcinomaPostoperative radiation therapy of pT2-3N0M0 esophageal carcinoma-a review.Prognostic impact of array-based genomic profiles in esophageal squamous cell cancer.Expression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinomaiRHOM2-dependent regulation of ADAM17 in cutaneous disease and epidermal barrier functionVEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma.An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer.The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma.Gastric cancer and the epoch of immunotherapy approachesA pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinomaEpidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinomaPhosphorylated AKT1 is associated with poor prognosis in esophageal squamous cell carcinoma.Epidermal growth factor receptor expression in esophageal adenocarcinoma: relationship with tumor stage and survival after esophagectomy.High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis.Characterization of the expression and clinical features of epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in esophageal carcinomaRole of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of actionNimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia.Predictive and prognostic molecular markers in outcome of esophageal cancer.Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial.Small molecule signal transduction inhibitors for the treatment of solid tumors.New and emerging combination therapies for esophageal cancer.Assessment of epidermal growth factor receptor mutation/copy number and K-ras mutation in esophageal cancer.ErbB receptors in the biology and pathology of the aerodigestive tractERBBs in the gastrointestinal tract: recent progress and new perspectives.Emerging drugs for esophageal cancer.Prognostic significance of epidermal growth factor receptor in locally advanced esophageal squamous cell carcinoma for patients receiving chemoradiotherapy.Targeted therapies for metastatic esophagogastric cancerEmerging tyrosine kinase inhibitors for esophageal cancer.Investigational therapies targeting the ErbB family in oesophagogastric cancer.Emerging mAbs for the treatment of esophagogastric cancer.Cetuximab in patients with esophageal cancer: a systematic review and meta-analysis of randomized controlled trials.Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.Featured article: autophagic activation with nimotuzumab enhanced chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma.The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
P2860
Q26776198-B4DB3463-3B77-4E8D-B32C-CC0F5A0FC26AQ27011232-67EE9967-94AC-4F5C-8049-0FAC6EF4BF2DQ27853223-528FA409-8E8F-43FB-A096-401330AE2820Q28551507-64CB804B-E799-49E2-9269-393204824E4FQ30245279-F3C3A846-BEE3-45FE-9F27-C8ECEAFFD6FAQ33327744-BDF80955-7624-40B4-8AEA-B50968F2DBEDQ33592904-7E56DAE3-5969-40EE-8D68-6BB969817746Q33947954-D7D5D822-457F-4AF8-AD27-4D4432D2B847Q34753345-1BF8EA83-19FC-47F0-BF4F-43AC733616D3Q35130286-E6DD8436-B61C-4F3D-B291-E2FFBD13BED4Q35624456-1B4D8192-EF32-4417-BB49-BA4A260D90FEQ35625349-EB8DC099-508B-49E1-9F17-1C1046B859D2Q35667892-942FD520-934C-47BB-B586-C1D88E5E374CQ35870351-F58B30C8-7CCC-4D70-868A-86C171983BFEQ36027475-6C7F223F-CED0-465A-A89A-3C59F68351BEQ36076031-7B1D874C-7A82-4A49-B7A6-01CAE3361740Q36210986-68D9034C-C679-487F-987E-03EB0E7EF1D2Q36334562-B02FE34B-6DE1-4B06-A271-29401EEF63ABQ36475391-D4420FFC-C1A6-4A79-A97C-ADD7F16A5044Q36517741-393260C9-259E-4CAF-93F6-E27C11163913Q36526959-B963D5C3-58A8-41C2-895C-5D74CF774641Q36636695-A039CC89-E122-45F0-9293-4B8162E89BC4Q36801223-E932C6C8-1D90-40ED-9814-A270DC39A09BQ36895413-2B9F599F-EF25-499A-9DD1-89089F7782A6Q36996728-6342CF6C-9CBF-4F30-874A-F2D90368F6E4Q37121410-33C6B7AE-0937-484C-82AC-C67702E6F80CQ37263452-8FCF5ADC-FE83-42E2-A38D-FD541AF694F0Q37337542-3139CE27-DEDA-4472-9FC4-28FD08DCCE4BQ37488281-64A01C83-446D-44AB-99F1-B2A31A33DE3AQ37652493-D1BFDAC4-A8BC-40ED-A204-34792A1C4E38Q37836513-E2CB18E2-DE94-48C5-B2EC-0FF063A7FC5AQ38110962-0E036199-C0C9-4275-A59E-D337556C6369Q38221886-82890D67-8548-4849-AAE5-00839C296667Q38284597-2EB97D00-52C0-4437-8C2E-1B25F6EC1421Q38385570-E554EF02-F4BC-4011-8FB8-70911577CC11Q38412375-6C97E6BF-6C08-4FBA-BABD-F4C6DF1D870BQ38893852-561A0A52-5D51-493F-9398-1C1FB01D9FE6Q39015925-5D28A380-83F6-433A-883C-09CF439BF5A1Q39385922-F00DE37B-93D2-47A3-82A2-CA21757C8C5AQ39400573-F10377D5-0B19-4BC8-A7F2-319E9C0086A1
P2860
Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Diffuse EGFR staining is assoc ...... ophageal squamous cell cancer.
@ast
Diffuse EGFR staining is assoc ...... ophageal squamous cell cancer.
@en
type
label
Diffuse EGFR staining is assoc ...... ophageal squamous cell cancer.
@ast
Diffuse EGFR staining is assoc ...... ophageal squamous cell cancer.
@en
prefLabel
Diffuse EGFR staining is assoc ...... ophageal squamous cell cancer.
@ast
Diffuse EGFR staining is assoc ...... ophageal squamous cell cancer.
@en
P2093
P2860
P356
P1476
Diffuse EGFR staining is assoc ...... ophageal squamous cell cancer.
@en
P2093
C Bessaguet
J-P Metges
M Robaszkiewicz
V Conan-Charlet
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602625
P407
P577
2005-07-01T00:00:00Z
P5875
P6179
1042610094